AI Engines For more Details: Perplexity Kagi Labs You
Cardiovascular Health: L-Taurine has been shown to have beneficial effects on cardiovascular health. It may help regulate blood pressure by modulating the activity of ion channels in blood vessels, promoting vasodilation, and reducing arterial stiffness. Additionally, L-Taurine has antioxidant properties that can protect the heart from oxidative stress and reduce the risk of cardiovascular diseases such as heart disease and stroke.
Diabetes Management: L-Taurine has been investigated for its potential to improve insulin sensitivity and glucose metabolism, making it potentially beneficial for individuals with diabetes or metabolic syndrome. It may help regulate blood sugar levels, reduce insulin resistance, and improve lipid profiles, thereby lowering the risk of diabetes-related complications.
Neurological Disorders: L-Taurine plays a role in neurological function and has been studied for its potential neuroprotective effects. It may help protect neurons from oxidative stress, inhibit excitotoxicity, and modulate neurotransmitter release, making it potentially beneficial for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Eye Health: L-Taurine is found in high concentrations in the retina and has been shown to have protective effects on retinal cells. It may help prevent retinal degeneration, reduce the risk of age-related macular degeneration (AMD), and improve visual function.
Exercise Performance: L-Taurine supplementation has been studied for its potential to enhance exercise performance and muscle function. It may help improve endurance, reduce muscle fatigue, and enhance recovery following intense physical activity. Additionally, L-Taurine may help protect muscles from exercise-induced damage and promote muscle protein synthesis.
Liver Health: L-Taurine plays a role in bile acid conjugation and detoxification processes in the liver. It may help protect the liver from damage caused by toxins, alcohol, and oxidative stress. L-Taurine supplementation has been studied for its potential to improve liver function and reduce the risk of liver diseases such as non-alcoholic fatty liver disease (NAFLD) and liver cirrhosis.
Mood and Stress: L-Taurine has been investigated for its potential to modulate neurotransmitter activity and exert calming effects on the brain. It may help reduce anxiety, improve mood, and promote relaxation by modulating the activity of neurotransmitter receptors such as GABA and glycine receptors.
| Rank | Probiotic | Impact |
|---|---|---|
| order | Rhodospirillales | Reduces |
| species | Bifidobacterium adolescentis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Increases |
| species | Bifidobacterium pseudocatenulatum | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | -0.8 | |
| Acne | 1.4 | 0.3 | 3.67 |
| ADHD | 1.7 | 3.7 | -1.18 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.5 | 0.2 |
| Allergic Rhinitis (Hay Fever) | 2.3 | 0.6 | 2.83 |
| Allergies | 0.9 | 2.8 | -2.11 |
| Allergy to milk products | 2.6 | 0.3 | 7.67 |
| Alopecia (Hair Loss) | 0.4 | -0.4 | |
| Alzheimer's disease | 4.5 | 4.1 | 0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 1.4 | -0.75 |
| Ankylosing spondylitis | 0.4 | 1.8 | -3.5 |
| Anorexia Nervosa | 0.8 | 2.1 | -1.63 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 0.6 | 1.1 | -0.83 |
| Atherosclerosis | 0.3 | 1.4 | -3.67 |
| Atrial fibrillation | 2.6 | 2.5 | 0.04 |
| Autism | 6 | 3.4 | 0.76 |
| Barrett esophagus cancer | 0 | 0 | |
| benign prostatic hyperplasia | 0.5 | -0.5 | |
| Bipolar Disorder | 1.6 | 2.6 | -0.63 |
| Brain Trauma | 0.4 | 1.1 | -1.75 |
| Breast Cancer | 0.8 | 0.2 | 3 |
| Carcinoma | 2.2 | 2.8 | -0.27 |
| Celiac Disease | 2.7 | 1.9 | 0.42 |
| Cerebral Palsy | 0.9 | -0.9 | |
| Chronic Fatigue Syndrome | 2.7 | 1 | 1.7 |
| Chronic Kidney Disease | 0.3 | 0.8 | -1.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.5 | 1.2 |
| Chronic Urticaria (Hives) | 0.3 | 1 | -2.33 |
| Coagulation / Micro clot triggering bacteria | 1.5 | -1.5 | |
| Colorectal Cancer | 3 | 1.4 | 1.14 |
| Constipation | 1 | 0.5 | 1 |
| Coronary artery disease | 0.5 | 0.3 | 0.67 |
| COVID-19 | 3.7 | 5.3 | -0.43 |
| Crohn's Disease | 4.3 | 4.5 | -0.05 |
| cystic fibrosis | 0.6 | 1.3 | -1.17 |
| deep vein thrombosis | 0.3 | -0.3 | |
| Depression | 6.8 | 5.7 | 0.19 |
| Dermatomyositis | 0.9 | 0 | 0 |
| Eczema | 1.3 | 0.3 | 3.33 |
| Endometriosis | 0.3 | 2.3 | -6.67 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 3.5 | 1.6 | 1.19 |
| erectile dysfunction | 0.2 | 0.5 | -1.5 |
| Fibromyalgia | 1.8 | 1 | 0.8 |
| Functional constipation / chronic idiopathic constipation | 3 | 2.1 | 0.43 |
| gallstone disease (gsd) | 1.1 | 1.3 | -0.18 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0 | 0 |
| Generalized anxiety disorder | 0.8 | 0 | 0 |
| giant cell arteritis | 0.3 | 0.3 | |
| Glioblastoma | 1.2 | -1.2 | |
| Graves' disease | 3 | -3 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 2.4 | 0.8 | 2 |
| Hemorrhoidal disease, Hemorrhoids, Piles | 0.3 | 0.5 | -0.67 |
| Hidradenitis Suppurativa | 0.6 | -0.6 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.8 | 0.6 | 0.33 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.2 | 1 |
| hyperglycemia | 1.4 | 0.6 | 1.33 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 1.9 | -5.33 |
| hypersomnia | 1 | 0.3 | 2.33 |
| hypertension (High Blood Pressure | 1.5 | 4.5 | -2 |
| Hypothyroidism | 2.5 | 1.4 | 0.79 |
| Hypoxia | 0.5 | 0.6 | -0.2 |
| IgA nephropathy (IgAN) | 0.6 | 1.3 | -1.17 |
| Inflammatory Bowel Disease | 2.4 | 3.2 | -0.33 |
| Insomnia | 0.2 | 1.5 | -6.5 |
| Intelligence | 0.7 | 0.3 | 1.33 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 3.4 | 3 | 0.13 |
| Juvenile idiopathic arthritis | 0.6 | -0.6 | |
| Liver Cirrhosis | 2.9 | 3.5 | -0.21 |
| Long COVID | 6.8 | 6.5 | 0.05 |
| Low bone mineral density | 0.5 | 1.7 | -2.4 |
| Lung Cancer | 1 | 1.1 | -0.1 |
| ME/CFS with IBS | 1.1 | 0.2 | 4.5 |
| ME/CFS without IBS | 1.4 | 1.4 | |
| Menopause | 0.2 | 0.4 | -1 |
| Metabolic Syndrome | 6 | 7.3 | -0.22 |
| Mood Disorders | 8 | 6.9 | 0.16 |
| Multiple Sclerosis | 2.5 | 4 | -0.6 |
| Multiple system atrophy (MSA) | 1.5 | 0.7 | 1.14 |
| myasthenia gravis | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.8 | 0.6 | 0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.2 | 0.5 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 1.4 | -0.08 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | |
| Obesity | 3.4 | 6.1 | -0.79 |
| obsessive-compulsive disorder | 1.6 | 1 | 0.6 |
| Osteoarthritis | 0.4 | 0.5 | -0.25 |
| Osteoporosis | 0.3 | 0.9 | -2 |
| pancreatic cancer | 0.7 | 0.7 | |
| Parkinson's Disease | 2.8 | 4.3 | -0.54 |
| Polycystic ovary syndrome | 1.3 | 1.6 | -0.23 |
| Postural orthostatic tachycardia syndrome | 0.6 | 0.6 | |
| Premenstrual dysphoric disorder | 0.6 | 0.6 | 0 |
| primary biliary cholangitis | 1.1 | -1.1 | |
| Psoriasis | 2.1 | 2.1 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 4.7 | -0.52 |
| Rosacea | 0.4 | 1.4 | -2.5 |
| Schizophrenia | 2.8 | 4.1 | -0.46 |
| scoliosis | 1.3 | 0.2 | 5.5 |
| sensorineural hearing loss | 0.8 | 0.8 | |
| Sjögren syndrome | 2.9 | 1.4 | 1.07 |
| Sleep Apnea | 1.8 | 1.8 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.3 | 1.33 |
| Stress / posttraumatic stress disorder | 1.5 | 2.6 | -0.73 |
| Systemic Lupus Erythematosus | 2.2 | 2.1 | 0.05 |
| Tic Disorder | 1.4 | 1.4 | |
| Tourette syndrome | 0.5 | -0.5 | |
| Type 1 Diabetes | 1.2 | 1.8 | -0.5 |
| Type 2 Diabetes | 4.2 | 5.2 | -0.24 |
| Ulcerative colitis | 3.5 | 2.8 | 0.25 |
| Unhealthy Ageing | 1.1 | 0.9 | 0.22 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.